Trials / Completed
CompletedNCT02081014
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Xeris Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | G-Pen Mini™ (glucagon injection) | stable, pre-mixed, liquid glucagon for subcutaneous injection |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2014-03-07
- Last updated
- 2018-04-05
- Results posted
- 2016-05-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02081014. Inclusion in this directory is not an endorsement.